Presence of serum RalA and serum p53 autoantibodies in 1833 patients with various types of cancers.
Tatsuki NanamiIsamu HoshinoFumiaki ShiratoriSatoshi YajimaYoko OshimaTakashi SuzukiMasaaki ItoTakaki HiwasaAkiko KuwajimaHideaki ShimadaPublished in: International journal of clinical oncology (2021)
The combined use of s-RalA-Abs and s-p53-Abs tended to increase the positivity rate in all cancers, including Stage 0/I/II cancers.